Asia-Pacific’s medical devices industry saw a drop of 15.22% in deal activity during July 2022, when compared with the last 12-month average, led by Orbimed Advisors’ $80m venture financing deal with LifeWell, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 39 medical devices industry deals worth $271.4m were announced for the region in July 2022, against the 12-month average of 46 deals.
Of all the deal types, venture financing saw most activity in July 2022 with 36 transactions, representing a 92.3% share for the region.
In second place was M&A with three deals capturing a 7.7% share of the overall deal activity for the month.
In terms of value of deals, venture financing was the leading category in Asia-Pacific’s medical devices industry with $261.76m, followed by M&A $9.65m.
Asia-Pacific medical devices industry deals in July 2022: Top deals
The top five medical devices deals accounted for 56.9% of the overall value during July 2022.
The combined value of the top five medical devices deals stood at $154.48m, against the overall value of $271.4m recorded for the month.
The top five medical devices industry deals of July 2022 tracked by GlobalData were:
1) Orbimed Advisors $80m venture financing deal with LifeWell
2) The $29.8m venture financing of Beijing Yading Information Technology by Eastern Bell Capital,Haier Capital,Sinovation Ventures and Xingtuo Capital
3) Huatai Zijin Investment,Jointown Pharmaceutical Group,Nanjing New Industry Investment Group and Wenzhou Investment $14.93m venture financing deal with Nanjing Puguang Biotechnology
4) The $14.93m venture financing of Shanghai Keku Medical Technology by Puhua Capital and Qishen Venture Capital
5) Dachen Caizhi,Daoyuan Capital Management (Beijing),Guangzhou Anbiping Pharmaceutical Technology,Huihe Capital,Kaipu Biotechnology and Qiming Venture Partners $14.82m venture financing deal with Beijing Zhizhen Biotechnology
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.